Danaher's Q2 2026 non-GAAP core revenue growth outlook centers on company guidance for low-single-digit expansion, following Q1's reported +0.5% core increase and full-year target of 3% to 6%. Traders appear balanced across ranges given sequential improvement expectations from management, with bioprocessing momentum in consumables offsetting lingering China diagnostics and respiratory headwinds. Key differentiators include segment-level trends—biotechnology projected for mid-single-digit gains versus flatter diagnostics performance—and currency impacts estimated at +0.5% for the quarter. The July 21 earnings release will provide the first confirmation of these dynamics against analyst models.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato3%-4.5% 97%
0%-1.5% 50%
1.5%-3% 49%
<0% 42%
NUOVO
NUOVO
21 lug 2026
<0%
42%
0%-1.5%
50%
1.5%-3%
49%
3%-4.5%
97%
4.5%+
31%
3%-4.5% 97%
0%-1.5% 50%
1.5%-3% 49%
<0% 42%
NUOVO
NUOVO
21 lug 2026
<0%
$20 Vol.
42%
0%-1.5%
$0 Vol.
50%
1.5%-3%
$0 Vol.
49%
3%-4.5%
$0 Vol.
97%
4.5%+
$20 Vol.
31%
This market will resolve according to Danaher's non-GAAP core revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Danaher's Q2 2026 non-GAAP core revenue growth outlook centers on company guidance for low-single-digit expansion, following Q1's reported +0.5% core increase and full-year target of 3% to 6%. Traders appear balanced across ranges given sequential improvement expectations from management, with bioprocessing momentum in consumables offsetting lingering China diagnostics and respiratory headwinds. Key differentiators include segment-level trends—biotechnology projected for mid-single-digit gains versus flatter diagnostics performance—and currency impacts estimated at +0.5% for the quarter. The July 21 earnings release will provide the first confirmation of these dynamics against analyst models.
This market will resolve according to Danaher's non-GAAP core revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Mercato aperto: Jul 8, 2026, 7:06 PM ET
Volume
$40Data di fine
21 lug 2026Mercato aperto
Jul 8, 2026, 7:06 PM ETResolver
0x69c47De9D...This market will resolve according to Danaher's non-GAAP core revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Danaher's Q2 2026 non-GAAP core revenue growth outlook centers on company guidance for low-single-digit expansion, following Q1's reported +0.5% core increase and full-year target of 3% to 6%. Traders appear balanced across ranges given sequential improvement expectations from management, with bioprocessing momentum in consumables offsetting lingering China diagnostics and respiratory headwinds. Key differentiators include segment-level trends—biotechnology projected for mid-single-digit gains versus flatter diagnostics performance—and currency impacts estimated at +0.5% for the quarter. The July 21 earnings release will provide the first confirmation of these dynamics against analyst models.
This market will resolve according to Danaher's non-GAAP core revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$40Data di fine
21 lug 2026Mercato aperto
Jul 8, 2026, 7:06 PM ETResolver
0x69c47De9D...Danaher's Q2 2026 non-GAAP core revenue growth outlook centers on company guidance for low-single-digit expansion, following Q1's reported +0.5% core increase and full-year target of 3% to 6%. Traders appear balanced across ranges given sequential improvement expectations from management, with bioprocessing momentum in consumables offsetting lingering China diagnostics and respiratory headwinds. Key differentiators include segment-level trends—biotechnology projected for mid-single-digit gains versus flatter diagnostics performance—and currency impacts estimated at +0.5% for the quarter. The July 21 earnings release will provide the first confirmation of these dynamics against analyst models.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti